ClinicalTrials.gg
CompletedNCT03033069Updated Dec 8, 2021Results posted

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

A Phase 2 interventional study of Brexpiprazole and Sertraline in Stress Disorders, Post-Traumatic, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 54 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-12-08.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sertraline in Stress Disorders, Post-Traumatic — none open to participants now, none under way, none of them phase 3. Sertraline · Stress Disorders, Post-Traumatic.

Enrollment
4th of 21
336 · median 80
Started
2017
the only one that year
Phase 2
3 of 22
none open now
Registered
18th of 22
by date
Lead sponsor
3 of 22
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 22 studies testing sertraline in Stress Disorders, Post-Traumatic, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 2, and was the 18th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

None of the 22 studies testing sertraline in Stress Disorders, Post-Traumatic is open now. The open studies under Stress Disorders, Post-Traumatic, anywhere →

Where they have run

About sertraline

Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing sertraline in Stress Disorders, Post-Traumatic as a file.
02

Study summary

To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy with Zoloft (sertraline) in adults with PTSD.

Read the detailed description

This trial is designed to assess the efficacy, safety and tolerability of flexible dose brexpiprazole as monotherapy or as combination therapy with Zoloft (Sertraline) in adult participants with PTSD.

This study will consist of a continuous 12-week, double-blind treatment period with a 14-day follow-up.

03

Conditions studied

  • Stress Disorders, Post-Traumatic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants between the years of 18-65 with a diagnosis of PTSD (diagnosis can be made at screening)

Exclusion criteria

Exclusion Criteria:

  • Index trauma event >15 years before screening
  • Index trauma event at age \<16
  • Any traumatic event within 3 months of screening
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    Brexpiprazole + Sertraline

    Participants were administered oral brexpiprazole initial dose of 0.5 milligram (mg)/day plus sertraline initial dose of 50 mg/day. The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo based on dose titration/adjustment up to Week 12.

    Drug: Brexpiprazole · Drug: Sertraline · Drug: Sertraline Matching Placebo

  • Experimental
    Brexpiprazole

    Participants were administered oral brexpiprazole initial dose of 0.5 mg/day The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo up to Week 12.

    Drug: Brexpiprazole · Drug: Sertraline Matching Placebo

  • Active comparator
    Sertraline

    Participants were administered oral sertraline initial dose of 50 mg/day. The dose was up titrated to sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received brexpiprazole matching placebo and sertraline matching placebo based on dose titration/adjustment up to Week 12.

    Drug: Sertraline · Drug: Brexpiprazole Matching Placebo · Drug: Sertraline Matching Placebo

  • Placebo comparator
    Placebo

    Participants received oral brexpiprazole matching placebo tablet and oral sertraline matching placebo capsules up to Week 12.

    Drug: Brexpiprazole Matching Placebo · Drug: Sertraline Matching Placebo

Interventions

  • Brexpiprazole oral tablets.

    Also known as: OPC-34712, OPC-331

  • Sertraline oral capsules.

    Also known as: Zoloft

  • DrugBrexpiprazole Matching Placebo

    Brexpiprazole matching placebo oral tablets.

  • DrugSertraline Matching Placebo

    Sertraline matching placebo oral capsules.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score

    CAPS-5:clinician-rated, structured interview to assess PTSD diagnostic status, symptoms severity as defined by DSM-5. CAPS-5 Past Week version of scale was completed at Baseline and at all visits after Baseline. CAPS-5 was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B:Intrusion symptoms (5 items); Category C:Avoidance symptoms (2 items); Category D:Cognition and mood symptoms (7 items); Category E:Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B,C,D,E. Each symptom was scored 0 (Absent) to 4 (Extreme/incapacitating), to yield a score with range 0-80. Higher scores=worse outcome. Mixed model repeated measure (MMRM) was used for analysis.

    Time frame: Baseline, Week 12

07

Results

Posted Dec 8, 2021

Participant flow

Participants took part in the study at 48 investigative sites in the United States from 26 January 2017 to 12 November 2018.

Participant flow — Overall Study
MilestoneBrexpiprazole + SertralineBrexpiprazoleSertralinePlacebo
Started82758183
Safety sample80757982
Intent to treat (itt) sample79727780
Completed58505964
Not completed24252219
Withdrew: Adverse event6746
Withdrew: Lack of efficacy0010
Withdrew: Lost to follow-up6556
Withdrew: Non-compliance with study drug1110
Withdrew: Protocol deviation0100
Withdrew: Withdrawal by subject1010116
Withdrew: Withdrawal by caregiver1000
Withdrew: Reason not specified0101

Outcome measures

PrimaryChange From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score

CAPS-5:clinician-rated, structured interview to assess PTSD diagnostic status, symptoms severity as defined by DSM-5. CAPS-5 Past Week version of scale was completed at Baseline and at all visits after Baseline. CAPS-5 was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B:Intrusion symptoms (5 items); Category C:Avoidance symptoms (2 items); Category D:Cognition and mood symptoms (7 items); Category E:Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B,C,D,E. Each symptom was scored 0 (Absent) to 4 (Extreme/incapacitating), to yield a score with range 0-80. Higher scores=worse outcome. Mixed model repeated measure (MMRM) was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score
score on a scaleBrexpiprazole + SertralineBrexpiprazoleSertralinePlacebo
Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score-16.4 ± 1.43-12.2 ± 1.57-11.4 ± 1.46-10.5 ± 1.40
Statistical analysis
  • Brexpiprazole + Sertraline vs Placebo · Mixed Model Repeated Measures (MMRM) · p = =0.0021 · Least squares (ls ) mean difference: -5.99 · 95% CI -9.79 to -2.19
  • Brexpiprazole vs Placebo · MMRM · p = =0.3868 · Ls mean difference: -1.74 · 95% CI -5.70 to 2.22
  • Sertraline vs Placebo · MMRM · p = =0.6399 · Ls mean difference: -0.91 · 95% CI -4.74 to 2.92
  • Brexpiprazole + Sertraline vs Sertraline · MMRM · p = =0.0106 · Ls mean difference: -5.08 · 95% CI -8.96 to -1.20
  • Brexpiprazole + Sertraline vs Brexpiprazole · MMRM · p = =0.0384 · Ls mean difference: -4.24 · 95% CI -8.26 to -0.23

Adverse events

Collected over From the first dose of the study drug up to 14 days after the last dose (Up to Week 14). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole + Sertraline0/80 (0%)2/80 (2.5%)47/80 (58.8%)
Brexpiprazole0/75 (0%)1/75 (1.3%)42/75 (56%)
Sertraline0/79 (0%)0/79 (0%)46/79 (58.2%)
Placebo1/82 (1.2%)4/82 (4.9%)43/82 (52.4%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole + SertralineBrexpiprazoleSertralinePlacebo
Animal biteInjury, poisoning and procedural complications0/801/750/790/82
Back painMusculoskeletal and connective tissue disorders1/800/750/791/82
Suicide attemptPsychiatric disorders1/800/750/790/82
Chest painGeneral disorders0/800/750/791/82
Bile duct stoneHepatobiliary disorders0/800/750/791/82
OsteonecrosisMusculoskeletal and connective tissue disorders0/800/750/791/82
Most frequent other events
Showing 10 of 20
Most frequent other events
EventBrexpiprazole + SertralineBrexpiprazoleSertralinePlacebo
NauseaGastrointestinal disorders4/801/7516/794/82
AkathisiaNervous system disorders5/8010/753/792/82
Dry mouthGastrointestinal disorders5/806/7510/797/82
Weight increaseInvestigations10/806/751/797/82
SomnolenceNervous system disorders8/805/753/797/82
Upper respiratory tract infectionInfections and infestations3/807/757/797/82
DiarrhoeaGastrointestinal disorders5/803/757/795/82
HeadacheNervous system disorders6/804/757/797/82
FatigueGeneral disorders2/806/754/790/82
Decreased appetiteMetabolism and nutrition disorders6/805/751/791/82

Baseline characteristics

Randomized Sample included all participants randomized into this trial.

Age, Continuous
Age, Continuous(years)Brexpiprazole + SertralineBrexpiprazoleSertralinePlaceboTotal
Mean38.4 ± 11.939.3 ± 10.638.6 ± 10.940.3 ± 11.039.2 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole + SertralineBrexpiprazoleSertralinePlaceboTotal
Female51495148199
Male31263035122
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole + SertralineBrexpiprazoleSertralinePlaceboTotal
Race — American Indian or Alaska Native11024
Race — Asian12014
Race — Native Hawaiian or Other Pacific Islander11002
Race — Black or African American2123222692
Race — White55435346197
Race — Other356822
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole + SertralineBrexpiprazoleSertralinePlaceboTotal
Ethnicity — Hispanic or Latino1311111449
Ethnicity — Not Hispanic or Latino68647069271
Ethnicity — Other10001
Region of Enrollment
Region of Enrollment(Participants)Brexpiprazole + SertralineBrexpiprazoleSertralinePlaceboTotal
United States82758183321
08

Study locations

54 sites
  • Investigational Site
    Tuscaloosa, Alabama 35404, United States
  • Investigational Site
    Phoenix, Arizona 85032, United States
  • Investigational Site
    Little Rock, Arkansas 72211, United States
  • Investigational Site
    Rogers, Arkansas 72758, United States
  • Investigational Site
    Bellflower, California 90706, United States
  • Investigational Site
    Beverly Hills, California 90210, United States
  • Investigational Site
    Glendale, California 91206, United States
  • Investigational Site
    National City, California 91950, United States
  • Investigational Site
    Oceanside, California 92054, United States
  • Investigational Site
    Oceanside, California 92056, United States
  • Investigational Site
    Orange, California 92868, United States
  • Investigational Site
    Redlands, California 92374, United States
  • Investigational Site
    Riverside, California 92506, United States
  • Investigational Site
    San Diego, California 92103, United States
  • Investigational Site
    San Marcos, California 92078, United States
  • Investigational Site
    Torrance, California 90502, United States
  • Investigational Site
    Colorado Springs, Colorado 80910, United States
  • Investigational Site
    Bradenton, Florida 34201, United States
  • Investigational Site
    Fort Lauderdale, Florida 33319, United States
  • Investigational Site
    Fort Myers, Florida 33912, United States
  • Investigational Site
    Gainesville, Florida 32607, United States
  • Investigational Site
    Jacksonville, Florida 32256, United States
  • Investigational Site
    North Miami, Florida 33161, United States
  • Investigational Site
    Orlando, Florida 32801, United States
  • Investigational Site
    Orlando, Florida 32806, United States
  • Investigational Site
    Tampa, Florida 33614, United States
  • Investigational Site
    Atlanta, Georgia 30341, United States
  • Investigational Site
    Decatur, Georgia 30030, United States
  • Investigational Site
    Roswell, Georgia 30076, United States
  • Investigational Site
    Chicago, Illinois 60640, United States
  • Investigational Site
    Saint Louis, Missouri 63141, United States
  • Investigational Site
    Las Vegas, Nevada 89102, United States
  • Investigational Site
    Berlin, New Jersey 08009, United States
  • Investigational Site
    Princeton, New Jersey 08540, United States
  • Investigational Site
    Brooklyn, New York 11235, United States
  • Investigational Site
    Cedarhurst, New York 11516, United States
  • Investigational Site
    New York, New York 10128, United States
  • Investigational Site
    Rochester, New York 14618, United States
  • Investigational Site
    Charlotte, North Carolina 28211, United States
  • Investigational Site
    Raleigh, North Carolina 27609, United States
  • Investigational Site
    Cincinnati, Ohio 45215, United States
  • Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site
    Oklahoma City, Oklahoma 73118, United States
  • Investigational Site
    Portland, Oregon 97214, United States
  • Investigational Site
    Salem, Oregon 97301, United States
  • Investigational Site
    Media, Pennsylvania 19063, United States
  • Investigational Site
    Norristown, Pennsylvania 19403, United States
  • Investigational Site
    Lincoln, Rhode Island 02865, United States
  • Investigational Site
    Charleston, South Carolina 29401, United States
  • Investigational Site
    Memphis, Tennessee 38119, United States
  • Investigational Site
    Bellaire, Texas 77401, United States
  • Investigational Site
    San Antonio, Texas 78229, United States
  • Investigational Site
    Wichita Falls, Texas 76309, United States
  • Investigational Site
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Nov 2018, 21 months.

Results were first posted in Dec 2021, 3 years after primary completion. A results delay was requested in Oct 2019.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 21 months is close to that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2017
First posted
Jan 26, 2017
StartActual
Jan 26, 2017
Primary completionActual
Nov 12, 2018
CompletionActual
Nov 12, 2018
Results delay requested
Oct 9, 2019
Results first posted
Dec 8, 2021
Last update
Dec 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03033069
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
Jan 26, 2017
Primary completion
Nov 12, 2018
Completion
Nov 12, 2018
Results posted
Dec 8, 2021
Last update
Dec 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Sertraline

Start the discussion